糖尿病肾病（Diabetic Kidney Disease，DKD）是糖尿病严重的肾脏并发症，中医药在 改善DKD症状及延缓病程进展方面疗效显著,尤其对早中期DKD有独特优势。中药复方糖耐康(TN K)是治疗DKD的临床经验方，在国家科技攻关计划、863课题等资助下，完成了临床前研究，获 临床研究批文，并完成二期临床试验，研究表明TNK能降低蛋白尿，改善肾脏纤维化，但是其 作用于足细胞损伤方面的机制尚不清楚。足细胞损伤是DKD病程进展的重要环节，本项目通过 糖耐康干预SHIP2抑制胰岛素信号通路介导的DKD足细胞损伤作用机制体内外实验研究，探讨中 药糖耐康防治DKD足细胞病变的作用机制，以解决中医药防治DKD关键科学问题，发展创新中医 理论，为中药防治DKD的研究提供新思路和新方法。

As a severe kidney complication of diabetes mellitus, diabetic kidney disease (DKD) is the major cause of disability and death in patients with diabetes. Chinese medicine has significant effect to improve the symptoms of DKD and delay the progression, especially for patients at an early or middle stage. Compound tangnaikang (TNK) is a clinical experience prescription to treat DKD. Its already completed the preclinical study, obtained the clinical research approval and completed the phase ii clinical trial under the support of the national science and technology program and the 863 project. Studies have shown that TNK can reduce proteinuria and improve renal fibrosis, but its mechanism is still unclear.Podocyte damage is an important link in DKD progression, SHIP2 high expression can inhibit insulin sensitivity which can lead to podotyte damage, therefore, this project is proposed by a successor intervention SHIP2 inhibit insulin signaling pathway mediated DKD podocyte damage experiments in vivo and in vitro studies, to explore a successor mechanism, prevention and control of DKD podocyte lesion DKD with TCM.   Discuss the targets and mechanisms of treatment of Tangnaikang, to develop and   innovate the theory of traditional Chinese medicine, provide new thoughts   and methods to treat and prevent   DKD by traditional Chinese medicine.